Fundz

Dynocardia, Inc. reported raising $350,000 in an initial SEC Form D filing, from an offering of $2 Million

PRIVATEFeb 14, 2020$350K of $2M raised

Amount Raised

$350,000

$350,000 sold, per SEC Form D (first sale Feb 14, 2020)

Round Type

Seed

CambridgeHealthcareHealth Care

Who else raised in Healthcare and Health Care around the same time

Companies in the same sectors as Dynocardia that raised within 45 days of this round, from Fundz verified event records.

  • CytoDyn raised $882K (Seed) on March 30, 2020.
  • Solana Company raised an undisclosed amount on March 30, 2020.
  • Monteris Medical raised $2.5M (Seed) on March 30, 2020.
  • AseptiScope, Inc. raised $230K (Seed) on March 27, 2020.
  • Olema Pharmaceuticals, Inc. raised $30M on March 27, 2020.
  • Interwell Health raised $20M on March 26, 2020.

Who to call at Dynocardia, and when

A new round usually means Dynocardia is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Dynocardia raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Dynocardia, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Dynocardia. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Dynocardia

Location

1188 CENTER STREET

Cambridge, Massachusetts, United States

About

Dynocardia is a biomedical device development company committed to satisfying critical unmet needs to improve healthcare worldwide. ViTrack™, our lead diagnostic device, is powered our proprietary technology making it the only stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. Unlike conventional occlusive devices, ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable, mobile, and easy to use, with the accuracy of intra-arterial lines. ViTrack, with data-rich capability that includes heart rate, heart rhythm, and respiratory parameters in addition to blood pressure, enables early intervention prior to acute events.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Dynocardia raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsJose W., Chief Product Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Dynocardia's next move

See what Strategic adds

Dynocardia raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.